Skip to content

Explore the Adbry Virtual Booth: Visit Now

Adbry for AD Logo Image

For the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

NOW APPROVED

The first and only biologic developed to specifically bind to and inhibit the IL-13 cytokine

Icon depicting a bar chart

See Proven Clinical Study Results

Efficacy results from three randomized, double-blind, placebo-controlled trials

See Results
Icon depicting a play button for the MOA

Discover How Adbry Works

A new, IL-13-targeted biologic therapy

Explore MOA
Adbry Advocate Logo

Learn About Access & Patient Support

Comprehensive patient support services through the Adbry™ Advocate™ Program.
Restrictions apply

Learn More